{"config":{"lang":["en"],"separator":"[\\s\\-]+","pipeline":["stopWordFilter"]},"docs":[{"location":"","title":"Research Project Documentation","text":"<p>A structured, science-centered template to plan, document, and evolve a research project across its full lifecycle.</p>"},{"location":"#about-this-template","title":"About This Template","text":"<p>This documentation site is built using the PhD Research Template structure. It provides a comprehensive framework for documenting research projects from hypothesis generation through results interpretation.</p>"},{"location":"#quick-navigation","title":"Quick Navigation","text":"<ul> <li>Research Design - Conceptual framing and scientific rationale</li> <li>Methods - Data sources, assumptions, and analytical decisions  </li> <li>Results - Interpretations and findings</li> <li>Tracking - Project evolution and timelines</li> <li>Collaboration - Team roles and sustainability</li> <li>Glossary - Key terms and definitions</li> </ul>"},{"location":"#getting-started","title":"Getting Started","text":"<ol> <li>Customize Configuration: Update <code>mkdocs.yml</code> with your project details</li> <li>Fill Core Documents: Start with the documents in each section</li> <li>Update Regularly: Keep documentation current as your research evolves</li> <li>Share: Use this site to share your work with collaborators and advisors</li> </ol>"},{"location":"#template-features","title":"Template Features","text":"<ul> <li>Structured Documentation: Organized sections for different aspects of your research</li> <li>Version Control: Track changes and decisions over time</li> <li>Searchable: Find information quickly across all documents</li> <li>Collaboration Ready: Easy to share with advisors and collaborators</li> <li>Reproducible: Clear documentation of methods and decisions</li> </ul>"},{"location":"#customization-guide","title":"Customization Guide","text":""},{"location":"#for-new-projects","title":"For New Projects","text":"<ol> <li> <p>Update the site metadata in <code>mkdocs.yml</code>:    <pre><code>site_name: Your Project Name\nsite_author: Your Name\nrepo_name: your-repo-name\nrepo_url: https://github.com/yourusername/your-repo-name\n</code></pre></p> </li> <li> <p>Modify the navigation structure to match your project's needs</p> </li> <li> <p>Add or remove sections based on your research requirements</p> </li> </ol>"},{"location":"#for-different-research-types","title":"For Different Research Types","text":"<ul> <li>Computational Research: Add sections for code documentation, algorithms, and computational methods</li> <li>Experimental Research: Add sections for protocols, equipment, and experimental procedures</li> <li>Clinical Research: Add sections for patient data, clinical protocols, and regulatory compliance</li> </ul>"},{"location":"#template-structure","title":"Template Structure","text":"<p>This template follows a systematic approach to research documentation:</p> <ul> <li>Research Design: Conceptual framework and scientific rationale</li> <li>Methods: Data sources, analytical approaches, and technical decisions</li> <li>Results: Findings, interpretations, and communication strategies</li> <li>Tracking: Project management, timelines, and decision logs</li> <li>Collaboration: Team structure, roles, and sustainability planning</li> </ul>"},{"location":"#contributing","title":"Contributing","text":"<p>This template is designed to be easily adaptable. Feel free to:</p> <ul> <li>Add new sections relevant to your research</li> <li>Modify the navigation structure</li> <li>Customize the styling and theme</li> <li>Share improvements with the community</li> </ul>"},{"location":"#license","title":"License","text":"<p>This template is provided under the MIT License. Use freely with attribution. </p>"},{"location":"LICENSE/","title":"License","text":"<p>MIT License</p> <p>Copyright \u00a9 2025 Shaurita D. Hutchins</p> <p>Permission is hereby granted, free of charge, to any person obtaining a copy of this software and associated documentation files (the \"Software\"), to deal in the Software without restriction, including without limitation the rights to use, copy, modify, merge, publish, distribute, sublicense, and/or sell copies of the Software, and to permit persons to whom the Software is furnished to do so, subject to the following conditions:</p> <p>The above copyright notice and this permission notice shall be included in all copies or substantial portions of the Software.</p> <p>THE SOFTWARE IS PROVIDED \"AS IS\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM, OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE SOFTWARE.</p>"},{"location":"glossary/","title":"Research Glossary","text":"<p>Here are key terms related to research methodology and computational biology.</p>"},{"location":"glossary/#aracne","title":"ARACNe","text":"<p>A mutual information-based algorithm used to reconstruct transcriptional networks by removing indirect interactions between transcription factors and their targets.</p>"},{"location":"glossary/#bias","title":"Bias","text":"<p>A systematic error that leads to incorrect estimates of effect or association. Can emerge from flawed design, measurement, or analysis.</p>"},{"location":"glossary/#blinding","title":"Blinding","text":"<p>The process of withholding knowledge of group assignment from participants, investigators, or analysts to reduce bias. Can be single- or double-blind.</p>"},{"location":"glossary/#bootstrap","title":"Bootstrap","text":"<p>A resampling method used to estimate statistics (like confidence intervals) from data by repeatedly sampling with replacement. Useful for evaluating uncertainty in high-dimensional biological data.</p>"},{"location":"glossary/#cadd","title":"CADD","text":"<p>Combined Annotation Dependent Depletion; a score that integrates multiple annotations to predict the deleteriousness of genetic variants in a genome-wide context.</p>"},{"location":"glossary/#case-control-study","title":"Case-Control Study","text":"<p>An observational design comparing individuals with a specific outcome (cases) to those without it (controls) to identify prior exposures.</p>"},{"location":"glossary/#causal-inference","title":"Causal Inference","text":"<p>The process of drawing conclusions about a causal relationship between variables, often through experimental or quasi-experimental designs.</p>"},{"location":"glossary/#censoring","title":"Censoring","text":"<p>A condition in survival analysis where the full event time is not observed for all subjects. Common in clinical and longitudinal genomic studies.</p>"},{"location":"glossary/#centimorgan","title":"Centimorgan","text":"<p>A unit of genetic linkage representing a 1% chance that a marker at one genetic locus will be separated from a marker at another locus due to crossing over in a single generation.</p>"},{"location":"glossary/#cohort-study","title":"Cohort Study","text":"<p>An observational design where a group is followed over time to assess how exposures affect outcomes.</p>"},{"location":"glossary/#confounding","title":"Confounding","text":"<p>A hidden factor that influences both the exposure and the outcome, potentially biasing the observed relationship and threatening causal inference.</p>"},{"location":"glossary/#construct-validity","title":"Construct Validity","text":"<p>The extent to which a test or tool actually measures the concept it intends to measure.</p>"},{"location":"glossary/#control-group","title":"Control Group","text":"<p>A group in a study that does not receive the experimental treatment and serves as a benchmark for comparison.</p>"},{"location":"glossary/#cross-sectional-study","title":"Cross-Sectional Study","text":"<p>A snapshot study that observes a population at a single point in time, often used to assess prevalence.</p>"},{"location":"glossary/#design","title":"Design","text":"<p>The structured logic and architecture of how you test your ideas. Good design minimizes bias, controls variation, and clarifies causal relationships.</p>"},{"location":"glossary/#differential-expression","title":"Differential Expression","text":"<p>A computational method used to detect genes with statistically significant changes in expression between conditions (e.g., disease vs. control).</p>"},{"location":"glossary/#double-blind","title":"Double-Blind","text":"<p>A study design where both participants and investigators are unaware of treatment assignments to reduce expectancy effects and bias.</p>"},{"location":"glossary/#effect-size","title":"Effect Size","text":"<p>A quantitative measure of the magnitude of a phenomenon. Important for interpreting the practical significance of results.</p>"},{"location":"glossary/#experimental","title":"Experimental","text":"<p>A study design where participants or units are randomly assigned to different conditions or treatments to test causal effects.</p>"},{"location":"glossary/#external-validity","title":"External Validity","text":"<p>The degree to which study findings generalize beyond the specific sample, setting, or time in which the study was conducted.</p>"},{"location":"glossary/#fair-metadata","title":"FAIR Metadata","text":"<p>Metadata adhering to the principles of Findability, Accessibility, Interoperability, and Reusability, supporting data sharing and reproducibility.</p>"},{"location":"glossary/#false-discovery-rate-fdr","title":"False Discovery Rate (FDR)","text":"<p>The expected proportion of false positives among all significant results. Frequently used in genomics to adjust for multiple hypothesis testing.</p>"},{"location":"glossary/#feature-selection","title":"Feature Selection","text":"<p>The process of selecting a subset of relevant variables (genes, proteins, etc.) for model building in high-dimensional biological data.</p>"},{"location":"glossary/#generalizability","title":"Generalizability","text":"<p>The extent to which results from a sample or model apply to other populations, settings, or times.</p>"},{"location":"glossary/#gene-regulatory-network","title":"Gene Regulatory Network","text":"<p>A system of transcription factors, genes, and regulatory interactions that governs gene expression patterns. Often modeled as directed graphs to understand cellular responses and disease mechanisms.</p>"},{"location":"glossary/#gpu","title":"GPU","text":"<p>Graphics Processing Unit; a parallel processing hardware component originally developed for rendering images, now widely used to accelerate computation in machine learning, graph analytics, and bioinformatics workflows.</p>"},{"location":"glossary/#graph-database","title":"Graph Database","text":"<p>A database structured as a graph where data entities are nodes and relationships are edges. Supports efficient querying of connected data. Examples include Neo4j and Amazon Neptune.</p>"},{"location":"glossary/#graph-theory","title":"Graph Theory","text":"<p>The mathematical study of graphs as representations of pairwise relationships between objects. Key concepts include centrality, clustering, and motifs.</p>"},{"location":"glossary/#heilmeier-catechism","title":"Heilmeier Catechism","text":"<p>A set of vetting questions developed by George Heilmeier to evaluate the feasibility, impact, and clarity of research proposals. Commonly used by funding agencies (e.g., DARPA) to assess whether a project is well-posed, high-impact, and realistic.</p>"},{"location":"glossary/#hetionet","title":"Hetionet","text":"<p>A heterogeneous biomedical knowledge graph integrating entities such as genes, diseases, drugs, and pathways, used to infer mechanistic links and support hypothesis generation.</p>"},{"location":"glossary/#hidden-confounder","title":"Hidden Confounder","text":"<p>An unobserved variable that correlates with both predictor and outcome, leading to biased associations. Addressed using surrogate variable analysis or latent factor models.</p>"},{"location":"glossary/#hypothesis","title":"Hypothesis","text":"<p>A specific, testable statement about the relationship between variables. For example: \"Modifier variants cluster in immune regulatory genes.\"</p>"},{"location":"glossary/#internal-validity","title":"Internal Validity","text":"<p>The degree to which observed effects can be attributed to the experimental variable rather than confounding factors or methodological artifacts.</p>"},{"location":"glossary/#kgqa","title":"KGQA","text":"<p>Knowledge Graph Question Answering; an approach that enables querying structured biological knowledge using natural language mapped to graph traversal or SPARQL logic.</p>"},{"location":"glossary/#knockout-model","title":"Knockout Model","text":"<p>A genetic experimental design where a gene is intentionally disrupted or deleted to study its function or role in disease.</p>"},{"location":"glossary/#langchain","title":"LangChain","text":"<p>A software framework that connects large language models to external tools, databases, and APIs for composable reasoning or document-grounded tasks.</p>"},{"location":"glossary/#latent-variable","title":"Latent Variable","text":"<p>A variable that is not directly observed but is inferred from other variables (e.g., unobserved batch effects in RNA-seq data).</p>"},{"location":"glossary/#linkage-analysis","title":"Linkage Analysis","text":"<p>A statistical method used to map genetic loci by examining the co-segregation of markers with traits in families. Often expressed in centimorgans and useful for identifying candidate regions in rare disease studies.</p>"},{"location":"glossary/#matching","title":"Matching","text":"<p>A method used in observational or quasi-experimental studies to pair subjects in treatment and control groups based on shared characteristics to reduce bias.</p>"},{"location":"glossary/#mermaidjs","title":"Mermaid.js","text":"<p>A JavaScript library that allows users to generate diagrams and flowcharts from plain text, commonly used to represent workflows, graphs, and networks visually.</p>"},{"location":"glossary/#meta-analysis","title":"Meta-Analysis","text":"<p>A statistical method for combining results from multiple studies to derive a more precise estimate of effect size or significance.</p>"},{"location":"glossary/#natural-experiment","title":"Natural Experiment","text":"<p>A naturally occurring situation that mimics the structure of an experiment, such as a policy change or environmental event, allowing for comparative analysis.</p>"},{"location":"glossary/#network-inference","title":"Network Inference","text":"<p>The computational process of reconstructing biological networks (e.g., gene-gene, protein-protein, regulatory) from high-throughput data using statistical or machine learning algorithms.</p>"},{"location":"glossary/#observational","title":"Observational","text":"<p>A non-interventional study design that documents relationships among variables without manipulating them. Common in epidemiology, social science, and public health.</p>"},{"location":"glossary/#overfitting","title":"Overfitting","text":"<p>A modeling error where a statistical model captures noise instead of the underlying signal, reducing its generalizability to new data.</p>"},{"location":"glossary/#panda","title":"PANDA","text":"<p>Passing Attributes between Networks for Data Assimilation; a computational method for integrating gene expression, TF binding, and protein interaction data to infer gene regulatory networks.</p>"},{"location":"glossary/#power","title":"Power","text":"<p>The probability that a study will detect a true effect when it exists. Depends on effect size, sample size, and significance threshold.</p>"},{"location":"glossary/#project-timeline","title":"Project Timeline","text":"<p>A structured outline of the phases and estimated durations of the research process, including proposal, data collection, analysis, and writing.</p>"},{"location":"glossary/#proposal-abstract","title":"Proposal Abstract","text":"<p>A short summary of the planned research that includes background, aims, and significance. Required in most graduate and funding proposals.</p>"},{"location":"glossary/#protege","title":"Prot\u00e9g\u00e9","text":"<p>An open-source ontology editor and knowledge modeling tool used to build and visualize OWL and RDF graphs. Frequently used for biomedical ontologies.</p>"},{"location":"glossary/#pseudo-autosomal","title":"Pseudo-Autosomal","text":"<p>Refers to regions on the sex chromosomes (e.g., PAR1 and PAR2) where homologous recombination occurs between X and Y during meiosis. These regions escape X-inactivation and require special handling in genomic analyses.</p>"},{"location":"glossary/#pseudoreplication","title":"Pseudoreplication","text":"<p>The error of treating non-independent observations as independent, leading to inflated sample sizes and false positives.</p>"},{"location":"glossary/#quasi-experimental","title":"Quasi-Experimental","text":"<p>A study design that compares groups with an intervention but lacks random assignment. May include pre-post comparisons or matched groups.</p>"},{"location":"glossary/#random-assignment","title":"Random Assignment","text":"<p>A method used in experiments to allocate units to conditions purely by chance, helping to control for bias and equate groups at baseline.</p>"},{"location":"glossary/#random-forest","title":"Random Forest","text":"<p>A machine learning method useful for classification and regression in biological datasets, based on ensembles of decision trees.</p>"},{"location":"glossary/#random-sampling","title":"Random Sampling","text":"<p>A method of selecting a representative subset of a population, often used to generalize findings to a broader group.</p>"},{"location":"glossary/#renet2","title":"RENET2","text":"<p>A deep learning-based tool for extracting gene-disease associations from biomedical literature using named entity recognition and relation classification.</p>"},{"location":"glossary/#rdf","title":"RDF","text":"<p>Resource Description Framework; a data model for representing information in graphs using triples (subject\u2013predicate\u2013object), forming the basis of the semantic web.</p>"},{"location":"glossary/#regression-discontinuity-design","title":"Regression Discontinuity Design","text":"<p>A quasi-experimental approach where participants are assigned to groups based on a cutoff score on a pre-intervention variable.</p>"},{"location":"glossary/#reliability","title":"Reliability","text":"<p>The degree to which a measure or study produces consistent and repeatable results.</p>"},{"location":"glossary/#research-aims","title":"Research Aims","text":"<p>Concise statements of specific goals the project intends to achieve, often broken into Aim 1, Aim 2, etc., especially in NIH-style grants.</p>"},{"location":"glossary/#research-design","title":"Research Design","text":"<p>The overall strategy for integrating different components of the study\u2014experimental logic, sampling, analysis\u2014to test hypotheses effectively.</p>"},{"location":"glossary/#rna-seq","title":"RNA-seq","text":"<p>A sequencing-based method to quantify gene expression, frequently used in transcriptome analysis, disease mechanism exploration, and biomarker discovery.</p>"},{"location":"glossary/#selection-bias","title":"Selection Bias","text":"<p>A distortion in the estimation of effect due to systematic differences in the characteristics of those selected for study groups.</p>"},{"location":"glossary/#sensitivity-analysis","title":"Sensitivity Analysis","text":"<p>An approach to test the robustness of results to changes in model assumptions or data input. Often used to assess how parameter choices affect results.</p>"},{"location":"glossary/#shacl","title":"SHACL","text":"<p>Shapes Constraint Language; a W3C standard used to define validation rules and constraints over RDF graphs, ensuring consistency in structured data.</p>"},{"location":"glossary/#single-blind","title":"Single-Blind","text":"<p>A design in which participants are unaware of their group assignment, but investigators are not blinded.</p>"},{"location":"glossary/#snakemake","title":"Snakemake","text":"<p>A workflow management system used in bioinformatics to define reproducible data processing pipelines using a rule-based format and dependency tracking.</p>"},{"location":"glossary/#sparql","title":"SPARQL","text":"<p>A query language for retrieving and manipulating data stored in RDF format. Used in semantic web and knowledge graph querying.</p>"},{"location":"glossary/#statistical-significance","title":"Statistical Significance","text":"<p>A result unlikely to have occurred by chance, according to a predefined threshold (typically p &lt; 0.05).</p>"},{"location":"glossary/#survival-analysis","title":"Survival Analysis","text":"<p>A class of statistical methods for analyzing time-to-event data. Widely used in genomics, especially for cancer prognosis.</p>"},{"location":"glossary/#systems-biology","title":"Systems Biology","text":"<p>An integrative field that models complex interactions between biological entities (genes, proteins, metabolites) across scales.</p>"},{"location":"glossary/#time-series-design","title":"Time Series Design","text":"<p>A study design involving repeated observations over time\u2014before, during, and after an intervention or event. It is often used to detect trends, interruptions, or delayed effects. Time series designs can help distinguish causal effects from background noise by analyzing change patterns across multiple time points, especially when randomization is not feasible.</p>"},{"location":"glossary/#translational-research","title":"Translational Research","text":"<p>Research aimed at moving discoveries from bench to bedside, such as identifying candidate biomarkers or repurposing drugs using computational approaches.</p>"},{"location":"glossary/#trust-graph","title":"Trust Graph","text":"<p>A graph representation used to document the provenance, reliability, and decision traceability of computational outputs, especially in explainable AI systems.</p>"},{"location":"glossary/#validation-set","title":"Validation Set","text":"<p>A separate subset of data used to test model generalization after training. Important in computational modeling to avoid overfitting.</p>"},{"location":"glossary/#validity","title":"Validity","text":"<p>The degree to which a method or result accurately reflects what it is intended to measure or infer.</p>"},{"location":"glossary/#wgcna","title":"WGCNA","text":"<p>Weighted Gene Co-expression Network Analysis; a method for identifying modules of highly correlated genes and relating them to sample traits or phenotypes.</p>"},{"location":"references/","title":"Project References","text":"<p>This file collects foundational and frequently cited literature relevant to this project. It is grouped thematically and intended as a living resource. Use this file when drafting papers, proposals, or onboarding collaborators.</p>"},{"location":"references/#variant-interpretation-and-modifier-models","title":"Variant Interpretation and Modifier Models","text":"<ul> <li>Lek et al. (2016). Analysis of protein-coding genetic variation in 60,706 humans. Nature, 536(7616), 285\u2013291.</li> </ul>"},{"location":"references/#rare-disease-and-pah-mechanisms","title":"Rare Disease and PAH Mechanisms","text":"<ul> <li>Austin et al. (2012). BMPR2 expression is reduced in endothelial cells exposed to serum from patients with heritable PAH. Circulation Research, 111(5), 561\u2013574.</li> </ul>"},{"location":"references/#computational-tools-and-pipelines","title":"Computational Tools and Pipelines","text":"<ul> <li>Love et al. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biology, 15(12), 550.</li> </ul>"},{"location":"references/#systems-modeling-and-network-biology","title":"Systems Modeling and Network Biology","text":"<ul> <li>Barab\u00e1si et al. (2011). Network medicine: a network-based approach to human disease. Nature Reviews Genetics, 12(1), 56\u201368.</li> <li>Greene et al. (2015). Understanding multicellular function and disease with human tissue-specific networks. Nature Genetics, 47(6), 569\u2013576.</li> </ul>"},{"location":"references/#general-guidance-for-computational-biology-projects","title":"General Guidance for Computational Biology Projects","text":"<ul> <li>Noble, W. S. (2022). Ten simple rules for defining a computational biology project. PLOS Computational Biology, 18(12), e1010742.</li> </ul>"},{"location":"references/#ethics-equity-and-reproducibility","title":"Ethics, Equity, and Reproducibility","text":"<ul> <li>Sandve et al. (2013). Ten simple rules for reproducible computational research. PLOS Computational Biology, 9(10), e1003285.</li> </ul>"},{"location":"references/#formatting-suggestions","title":"Formatting Suggestions","text":"<ul> <li>Prefer short citation blocks: Author, Year, Title, Journal</li> <li>Group by theme, not file</li> <li>Update when citing in major reports or methods</li> </ul>"},{"location":"collaboration/handoff_plan/","title":"Continuity Plan","text":"<ul> <li>If unavailable, who can maintain project?</li> <li>What is documented?</li> <li>Transition notes:</li> </ul>"},{"location":"collaboration/project_roles/","title":"Project Roles","text":"<ul> <li>PI:</li> <li>Day-to-day lead:</li> <li>Statistical/bioinformatics support:</li> <li>Clinical or domain collaborators:</li> </ul>"},{"location":"collaboration/review_calendar/","title":"Review Milestones","text":"Date Milestone Notes Initial proposal review Midterm check-in"},{"location":"collaboration/sustainability_notes/","title":"Long-term Maintenance Plan","text":"<ul> <li>Will this tool/project persist after graduation?</li> <li>Who funds or supports it?</li> <li>Publication/archive plan:</li> </ul>"},{"location":"methods/analysis_plan/","title":"Analysis Plan","text":"<p>This section outlines your planned analyses and statistical reasoning. It serves as a roadmap for turning raw data into interpretable results.</p>"},{"location":"methods/analysis_plan/#core-questions","title":"Core Questions","text":"<ul> <li>What are the main hypotheses or questions you are testing?<ul> <li>Example: \u201cDo expression outliers cluster in enhancer-linked genes in the disease group?\u201d</li> </ul> </li> <li>Are there secondary analyses, subgroup evaluations, or exploratory components?</li> </ul>"},{"location":"methods/analysis_plan/#design-justification","title":"Design Justification","text":"<ul> <li>Why is your study design appropriate for the analysis?<ul> <li>Example: \u201cWe use a quasi-experimental design with matched controls to reduce confounding.\u201d</li> </ul> </li> <li>Are you using repeated measures, batch correction, or stratification?</li> </ul>"},{"location":"methods/analysis_plan/#methods-overview","title":"Methods Overview","text":"<ul> <li>What statistical or computational methods will you use?<ul> <li>Examples: DESeq2, mixed-effects models, PCA, Bayesian models, permutation tests</li> </ul> </li> <li>How will you control for multiple testing or reduce dimensionality?</li> </ul>"},{"location":"methods/analysis_plan/#dependencies-and-assumptions","title":"Dependencies and Assumptions","text":"<ul> <li>What assumptions does your analysis rely on (e.g., normality, independence, linearity)?</li> <li>Are there known data limitations (e.g., batch effects, missing values, unbalanced groups)?</li> <li>How will you test or account for violations?</li> </ul>"},{"location":"methods/analysis_plan/#power-and-sample-considerations-optional","title":"Power and Sample Considerations (optional)","text":"<ul> <li>Is there a power analysis? If not, why?</li> <li>Minimum sample size required to detect a meaningful effect?</li> </ul>"},{"location":"methods/controls_and_nulls/","title":"Controls and Null Models","text":"<p>This section helps clarify how your study will distinguish signal from noise and guard against spurious conclusions. Controls and nulls support interpretation and increase confidence in findings.</p>"},{"location":"methods/controls_and_nulls/#controls","title":"Controls","text":"<ul> <li>What negative controls are used?<ul> <li>Example: Samples with no expected expression change under treatment.</li> </ul> </li> <li>What positive controls are included?<ul> <li>Example: A known pathogenic variant or gold-standard dataset.</li> </ul> </li> </ul>"},{"location":"methods/controls_and_nulls/#null-models","title":"Null Models","text":"<ul> <li>What is the structure of your null model?<ul> <li>Example: Permuted sample labels; shuffled gene-gene interaction network; simulated VCFs.</li> </ul> </li> <li>How does your null model match the structure or distribution of your real data?</li> <li>Why is this model appropriate for isolating your signal?</li> </ul>"},{"location":"methods/controls_and_nulls/#randomization-permutation-strategy","title":"Randomization / Permutation Strategy","text":"<ul> <li>Are you using label permutation, bootstrapping, or synthetic sampling?</li> <li>How many iterations will be run?</li> <li>What assumptions are held constant across randomizations?</li> </ul>"},{"location":"methods/controls_and_nulls/#interpretation-framework","title":"Interpretation Framework","text":"<ul> <li>How will you compare observed results to null expectations?<ul> <li>p-values, empirical FDR, effect size thresholds?</li> </ul> </li> <li>Do your controls and nulls provide calibration or sanity checks for core methods?</li> </ul>"},{"location":"methods/data_and_software_doc/","title":"Reproducibility Notes","text":"<ul> <li>Software versions and environments:</li> <li>Containerized workflows:</li> <li>Code/data locations and access:</li> </ul>"},{"location":"methods/data_sources/","title":"Data Sources","text":"<p>Document the origin, structure, and preprocessing of datasets used in your project. This section supports transparency, reproducibility, and critical appraisal of the underlying evidence base.</p>"},{"location":"methods/data_sources/#source-datasets-and-descriptions","title":"Source Datasets and Descriptions","text":"<ul> <li>Where did each dataset originate (e.g., public database, collaborator, institutional study)?<ul> <li>Example: GTEx v8 RNA-seq data for 17 tissues; dbGaP accession phs001234.v1 for whole-genome sequencing of PAH cohort.</li> </ul> </li> <li>What kind of data is included (e.g., raw FASTQ, VCF, count matrices, clinical annotations)?<ul> <li>Example: Processed gene counts (TPM, raw) and matched genotype data for 300 individuals.</li> </ul> </li> </ul>"},{"location":"methods/data_sources/#cohorts-and-sample-sizes","title":"Cohorts and Sample Sizes","text":"<ul> <li>What populations or models are represented?<ul> <li>Example: 105 BMPR2 mutation carriers (40 affected, 65 unaffected); 50 healthy controls.</li> </ul> </li> <li>Are there subgroups of interest (e.g., stratified by sex, ancestry, disease subtype)?<ul> <li>Example: Stratification by WHO PAH subtype and family structure.</li> </ul> </li> </ul>"},{"location":"methods/data_sources/#preprocessing-or-curation-steps","title":"Preprocessing or Curation Steps","text":"<ul> <li>What transformations were applied to the raw data?<ul> <li>Example: Adapter trimming with Trim Galore, alignment with STAR, quantification via featureCounts.</li> </ul> </li> <li>How was quality control performed?<ul> <li>Example: Excluded samples with &lt;70% mapping rate or &lt;10M reads; removed genes with low variance across all samples.</li> </ul> </li> <li>Were any samples excluded or imputed? Why?<ul> <li>Example: Imputed missing genotypes using Beagle; removed mislabeled samples based on genotype PCA.</li> </ul> </li> </ul>"},{"location":"methods/data_sources/#data-use-and-access","title":"Data Use and Access","text":"<ul> <li>What are the data access constraints (e.g., open access, dbGaP-controlled, IRB approval)?</li> <li>Are any datasets sensitive (e.g., human subject data, Indigenous-controlled datasets)? What restrictions apply?</li> </ul>"},{"location":"methods/ethics_equity_practicalities/","title":"Ethical, Equity, and Practical Considerations","text":"<p>This section prompts critical reflection on how study design, implementation, and dissemination intersect with broader ethical, social, and logistical concerns. Update this document as issues arise or are resolved.</p>"},{"location":"methods/ethics_equity_practicalities/#inclusion-and-exclusion-biases","title":"Inclusion and Exclusion Biases","text":"<ul> <li>Who is represented in the data, and who is left out?<ul> <li>Examples: Predominantly European ancestry populations in genomic data; exclusion of pediatric or elderly cohorts.</li> </ul> </li> <li>What are the potential impacts of these biases on generalizability or fairness?</li> <li>Could decisions about inclusion criteria affect downstream interpretation or model behavior?</li> </ul>"},{"location":"methods/ethics_equity_practicalities/#open-science-and-data-sovereignty","title":"Open Science and Data Sovereignty","text":"<ul> <li>Will code, data, and findings be openly shared? What are the licensing and access models?</li> <li>Are there any constraints due to IRB, data use agreements, or tribal/sovereign rights?<ul> <li>Examples: Respecting Indigenous Data Sovereignty principles (e.g., CARE vs. FAIR).</li> </ul> </li> <li>How will authorship, credit, and contribution be transparently tracked?</li> </ul>"},{"location":"methods/ethics_equity_practicalities/#computational-constraints","title":"Computational Constraints","text":"<ul> <li>Are there limits in hardware, software, or pipeline reproducibility?<ul> <li>Examples: GPU access, reliance on proprietary tools, memory-intensive models.</li> </ul> </li> <li>Are backup or low-resource versions of the analysis feasible?</li> <li>Could practical limitations introduce bias (e.g., truncating sample size, skipping QC steps)?</li> </ul>"},{"location":"methods/ethics_equity_practicalities/#potential-harms-and-mitigations","title":"Potential Harms and Mitigations","text":"<ul> <li>Could this work be misused or misinterpreted (e.g., in clinical settings)?</li> <li>Are there safeguards or contextual notes included in outputs?</li> <li>How will error, uncertainty, and scope limitations be communicated to end users?</li> </ul>"},{"location":"methods/method_assumptions/","title":"Methodological Assumptions","text":"<p>Clearly articulating methodological assumptions helps clarify the limits of inference and flags potential sources of bias or error. This section should be updated as new methods are added or revised.</p>"},{"location":"methods/method_assumptions/#core-assumptions","title":"Core Assumptions","text":"<ul> <li>What assumptions are embedded in your statistical models, machine learning algorithms, or inference frameworks?<ul> <li>Examples: Linearity, independence, stationarity, uniform prior distribution, normality of residuals.</li> </ul> </li> </ul>"},{"location":"methods/method_assumptions/#domain-specific-assumptions","title":"Domain-Specific Assumptions","text":"<ul> <li>What biological or clinical assumptions are built into the design or interpretation?<ul> <li>Examples: Gene expression reflects protein activity, mutation burden correlates with phenotype severity.</li> </ul> </li> </ul>"},{"location":"methods/method_assumptions/#assumption-validation","title":"Assumption Validation","text":"<ul> <li>How will each assumption be tested, relaxed, or examined?<ul> <li>Examples: Residual diagnostics, simulation studies, cross-validation, external datasets.</li> </ul> </li> </ul>"},{"location":"methods/method_assumptions/#known-limitations","title":"Known Limitations","text":"<ul> <li>Which assumptions are unlikely to hold and what consequences might they have for results?</li> <li>Are any assumptions unverifiable but necessary for tractability?</li> </ul>"},{"location":"methods/method_assumptions/#revisions-or-exceptions","title":"Revisions or Exceptions","text":"<ul> <li>Log any changes to assumptions over time, along with justifications or supporting evidence.</li> </ul>"},{"location":"methods/pipeline_decisions/","title":"Pipeline Decisions","text":"<p>Document the primary analysis pipeline(s), justification for tool selection, and overall data flow. This helps others (and future you) understand the reasoning behind methodological choices.</p>"},{"location":"methods/pipeline_decisions/#pipeline-or-tool-used","title":"Pipeline or Tool Used","text":"<ul> <li>What software, workflow system, or pipeline is being used?<ul> <li>Example: Bulk RNA-seq pipeline built with Nextflow; variant annotation using VEP and Varsome API.</li> </ul> </li> <li>Is this an existing pipeline, modified version, or custom-built?<ul> <li>Example: Custom pipeline integrating Salmon for quantification and DESeq2 for differential expression.</li> </ul> </li> </ul>"},{"location":"methods/pipeline_decisions/#why-chosen","title":"Why Chosen","text":"<ul> <li>What are the strengths of the selected tool or framework?<ul> <li>Example: Nextflow allows modular execution across HPC and local machines.</li> </ul> </li> <li>How does the tool align with project needs (e.g., reproducibility, scalability, ease of debugging)?<ul> <li>Example: VEP offers transcript-aware variant annotation and integration with known pathogenicity scores.</li> </ul> </li> </ul>"},{"location":"methods/pipeline_decisions/#key-steps-and-data-flow","title":"Key Steps and Data Flow","text":"<ul> <li>What are the major stages of the pipeline?<ul> <li>Example: FASTQ \u2192 trimming \u2192 alignment \u2192 quantification \u2192 QC \u2192 normalization \u2192 statistical testing</li> </ul> </li> <li>Where are intermediate and final results stored?<ul> <li>Example: Intermediate BAM files stored under <code>/results/alignment/</code>; final DEGs in <code>/results/DESeq2/</code></li> </ul> </li> <li>How are logs, parameters, and environment versions handled?<ul> <li>Example: Conda environment YAML versioned with pipeline; logs stored in <code>.log/</code> and parameters in <code>config.yaml</code></li> </ul> </li> </ul>"},{"location":"methods/references/","title":"References","text":"<p>This file collects references specifically relevant to the methods of the project.</p>"},{"location":"methods/references/#key-papers","title":"Key Papers","text":"<ol> <li>Author(s), Year. Title. Journal Name, Volume(Issue), Pages.</li> <li>Author(s), Year. Tool related to this section.</li> </ol>"},{"location":"methods/references/#usage-or-notes","title":"Usage or Notes","text":"<ol> <li>Brief notes on how or where this reference informs current work (e.g., tool parameter selection, statistical justification, biological interpretation).</li> </ol>"},{"location":"methods/references/#to-review-or-vet","title":"To Review or Vet","text":"<ul> <li> Author(s), Year. Title. Still under consideration\u2014pending full read or discussion.</li> <li> Author(s), Year. Title. May be relevant if scope expands to [new topic].</li> </ul>"},{"location":"methods/references/#versioning-notes","title":"Versioning Notes","text":"<ul> <li>Last updated: [YYYY-MM-DD]</li> <li>Curated by: [Name]</li> </ul>"},{"location":"methods/tool_comparisons/","title":"Tool Comparisons","text":"<p>Use this section to transparently document why specific software tools, models, or algorithms were chosen over others. This aids reproducibility and clarifies methodological tradeoffs.</p>"},{"location":"methods/tool_comparisons/#candidate-tools-methods","title":"Candidate Tools / Methods","text":"<ul> <li>What tools or packages were considered?<ul> <li>Example: DESeq2, edgeR, and limma for differential expression analysis.</li> <li>Example: SIFT, CADD, REVEL, and DITTO for variant pathogenicity scoring.</li> </ul> </li> <li>What categories of tools were evaluated (e.g., alignment, clustering, dimensionality reduction)?</li> </ul>"},{"location":"methods/tool_comparisons/#comparison-criteria","title":"Comparison Criteria","text":"<ul> <li>What features or metrics were used to evaluate tools?<ul> <li>Examples: Runtime, scalability, documentation quality, accuracy in benchmark datasets, interpretability, community adoption.</li> </ul> </li> <li>Were test runs or pilot analyses conducted for direct comparison?<ul> <li>Example: Compared DEGs across tools using the same dataset; evaluated correlation with qPCR validation.</li> </ul> </li> </ul>"},{"location":"methods/tool_comparisons/#rejected-options-and-rationale","title":"Rejected Options and Rationale","text":"<ul> <li>What tools were not selected, and why?<ul> <li>Example: Excluded edgeR due to poor fit for low-count data; skipped SIFT due to outdated training data and limited transcript context.</li> </ul> </li> <li>Were there ethical, licensing, or reproducibility concerns?<ul> <li>Example: Did not select ToolX due to restrictive license incompatible with open-source goals.</li> </ul> </li> </ul>"},{"location":"research-design/design_type/","title":"Design Type","text":"<p>Select the overarching structure of your study. You may refine this later based on data availability and the types of inference required.</p> <ul> <li> <p> Experimental \u2013 An intervention (e.g., gene knockout, compound exposure) is applied to samples or systems with random assignment to treatment or control conditions. Maximizes internal validity and supports causal inference.  </p> <ul> <li>Example: Randomized CRISPR-based perturbation of transcription factors in iPSC-derived cardiomyocytes to assess regulatory cascade dynamics.</li> </ul> </li> <li> <p> Quasi-experimental \u2013 No full randomization, but structured comparisons exist (e.g., batch effects, pre/post treatment, matched controls). Common in studies constrained by patient groups, ethical considerations, or data reuse.  </p> <ul> <li>Example: Pre/post longitudinal RNA-seq analysis of PBMCs from patients before and after anti-TNF therapy initiation, without random assignment.</li> </ul> </li> <li> <p> Observational \u2013 Biological or clinical variation is measured without any applied intervention. This includes case-control, cohort, or cross-sectional studies using primary or secondary data (e.g., GTEx, TCGA, dbGaP).  </p> <ul> <li>Example: Integrating public TCGA RNA-seq data to identify expression signatures associated with TP53 mutation status across cancer types.</li> </ul> </li> </ul>"},{"location":"research-design/design_type/#design-rationale","title":"Design Rationale","text":"<ul> <li>Why is this design suitable for the biological or clinical system under study?</li> <li>Does your study involve interventions (e.g., CRISPR edits, drug screens), or are you analyzing pre-existing omics datasets?</li> <li>Are patient samples, tissues, or cell models pre-stratified by disease, genotype, or exposure?<ul> <li>Example: Matched case-control study of patients with idiopathic pulmonary fibrosis vs. unaffected siblings.</li> </ul> </li> <li>Which components of causal inference are strengthened or constrained by your design?<ul> <li>Example: Temporal resolution in a pre/post study supports causal ordering but lacks randomization.</li> </ul> </li> <li>What assumptions (e.g., no unmeasured confounding, correct time-ordering, linearity) are critical to justify your conclusions?<ul> <li>Example: Assuming no differential misclassification of exposure across outcome groups.</li> </ul> </li> <li>What tradeoffs are you accepting in exchange for feasibility, ethics, or biological realism?<ul> <li>Example: Using existing tissue biobank samples limits control over experimental consistency but enables access to rare phenotypes.</li> </ul> </li> </ul>"},{"location":"research-design/design_type/#control-strategy","title":"Control Strategy","text":"<ul> <li>What are your negative and/or positive controls (e.g., vehicle-treated samples, isogenic wild-type lines, healthy donors)?<ul> <li>Example: Untreated cell line replicates serve as negative controls; cells treated with known apoptosis inducer serve as positive control.</li> </ul> </li> <li>Are technical replicates, batch corrections, or normalization strategies in place to mitigate artifacts?<ul> <li>Example: ComBat used to adjust for batch effects across multiple sequencing runs.</li> </ul> </li> <li>What threats to validity are most relevant in your context (e.g., batch effects, immortal time bias, collider stratification)?<ul> <li>Example: Case/control imbalance across sequencing lanes introduces potential confounding.</li> </ul> </li> <li>How will you quantify or detect confounding? Are you planning to use statistical adjustment (e.g., covariate inclusion, inverse probability weighting)?<ul> <li>Example: Include sex, age, and batch as covariates in DESeq2 model.</li> </ul> </li> <li>Are your comparison groups biologically or clinically meaningful, or are they constructed for statistical contrast?<ul> <li>Example: Defining \"resilient\" vs. \"affected\" individuals with the same genotype to isolate protective transcriptomic signatures.</li> </ul> </li> </ul>"},{"location":"research-design/distinctions/","title":"Key Distinctions","text":"<p>Carefully defining your categorical boundaries ensures clarity in analysis, interpretation, and reproducibility. This section should surface how you\u2019re drawing scientific lines and the implications of those choices.</p>"},{"location":"research-design/distinctions/#core-categories","title":"Core Categories","text":"<ul> <li>What major distinctions are you drawing?<ul> <li>Example: Case vs. control; affected vs. unaffected carriers; treated vs. untreated</li> <li>Example: Driver variants vs. modifier variants; coding vs. regulatory elements</li> <li>Example: Early-onset vs. late-onset cases; cell type A vs. cell type B</li> </ul> </li> </ul>"},{"location":"research-design/distinctions/#in-scope-as-of-yyyy-mm-dd","title":"In-Scope (as of YYYY-MM-DD)","text":"<ul> <li>What\u2019s currently included in your study\u2019s scope?<ul> <li>Example: BMPR2 mutation carriers sequenced with &gt;30x WGS</li> <li>Example: Variants in genes with immune pathway annotation in GO or KEGG</li> <li>Example: Bulk RNA-seq from patient-derived fibroblasts in untreated state</li> </ul> </li> </ul>"},{"location":"research-design/distinctions/#out-of-scope-as-of-yyyy-mm-dd","title":"Out-of-Scope (as of YYYY-MM-DD)","text":"<ul> <li>What is currently excluded, and why?<ul> <li>Example: Pediatric samples due to consent restrictions</li> <li>Example: Functional assays requiring CRISPR validation</li> <li>Example: Single-cell resolution analysis (to be reserved for future aims)</li> </ul> </li> </ul>"},{"location":"research-design/distinctions/#risks-of-current-boundaries","title":"Risks of Current Boundaries","text":"<ul> <li>What are the analytical, ethical, or interpretive risks of the distinctions you\u2019re drawing?<ul> <li>Example: Bias due to uneven population sampling across case/control</li> <li>Example: Risk of excluding informative rare variants by current filter thresholds</li> <li>Example: Potential misclassification of modifiers as noise due to lack of phenotypic resolution</li> </ul> </li> </ul>"},{"location":"research-design/knowledge_gaps/","title":"Field Gaps","text":"<p>Use this section to articulate where the current body of research is limited, inconsistent, or incomplete. Focus on identifying precise methodological, mechanistic, or evidentiary shortcomings in the field you\u2019re contributing to.</p>"},{"location":"research-design/knowledge_gaps/#underexplored-or-overlooked-areas","title":"Underexplored or Overlooked Areas","text":"<ul> <li>What biological processes, model systems, or populations are understudied?<ul> <li>Example: Limited transcriptomic profiling of pulmonary endothelial cells from Black or Indigenous populations.</li> </ul> </li> <li>Are there diseases, subtypes, or phenotypes that lack genomic or molecular characterization?<ul> <li>Example: Rare pediatric-onset forms of systemic sclerosis lack genotype\u2013phenotype correlation studies.</li> </ul> </li> <li>Are there assumptions in standard models that have not been empirically tested?<ul> <li>Example: Assuming additive variant effects in polygenic risk scoring without modeling epistasis.</li> </ul> </li> </ul>"},{"location":"research-design/knowledge_gaps/#replication-and-reproducibility","title":"Replication and Reproducibility","text":"<ul> <li>Which published findings have not been independently validated?<ul> <li>Example: Network-based biomarker signatures proposed in small discovery cohorts, lacking external validation.</li> </ul> </li> <li>Are there inconsistencies across studies or datasets that suggest technical or biological variability?<ul> <li>Example: Discordant differential expression results across RNA-seq studies of the same disease due to batch effects or tissue sampling variability.</li> </ul> </li> <li>Are prior results based on small sample sizes, non-public data, or non-reproducible code?<ul> <li>Example: Use of unpublished clinical cohorts with inaccessible phenotype definitions or restricted pipelines.</li> </ul> </li> </ul>"},{"location":"research-design/knowledge_gaps/#mechanistic-gaps","title":"Mechanistic Gaps","text":"<ul> <li>What molecular or cellular mechanisms remain ambiguous or speculative?<ul> <li>Example: Unclear downstream effects of non-coding variants in enhancers regulating immune genes in autoimmune disease.</li> </ul> </li> <li>Are there known associations (e.g., variant\u2013phenotype, gene\u2013pathway) lacking causal explanation?<ul> <li>Example: Association between mitochondrial dysfunction and autism spectrum disorder without a mechanistic bridge from transcriptome to phenotype.</li> </ul> </li> <li>Where do data integration approaches fail to resolve underlying mechanisms?<ul> <li>Example: Single-cell and bulk RNA-seq integration yielding inconsistent pathway enrichment due to lack of normalization for cell composition.</li> </ul> </li> </ul>"},{"location":"research-design/knowledge_gaps/#computational-and-technical-gaps","title":"Computational and Technical Gaps","text":"<ul> <li>Are there limitations in current algorithms, tools, or pipelines (e.g., scalability, transparency, interpretability)?<ul> <li>Example: Graph neural networks for drug repurposing often lack explainable outputs or uncertainty quantification.</li> </ul> </li> <li>Is there a lack of standardization across datasets, ontologies, or metadata formats?<ul> <li>Example: Inconsistent phenotype naming across different rare disease consortia makes cross-cohort analysis difficult.</li> </ul> </li> <li>Are bias and generalizability concerns well-addressed in ML or statistical models?<ul> <li>Example: Deep learning models trained on TCGA data may underperform on underrepresented populations due to sampling bias.</li> </ul> </li> </ul>"},{"location":"research-design/knowledge_gaps/#opportunity-for-contribution","title":"Opportunity for Contribution","text":"<ul> <li>What would a successful study add to the field?<ul> <li>Example: A reproducible, phenotype-aware pipeline that integrates rare variant burden with tissue-specific co-expression networks.</li> </ul> </li> <li>How could your work fill one or more of these gaps with rigor?<ul> <li>Example: Using matched unaffected carriers and cases to identify transcriptional signatures that define resilience, validated across independent cohorts.</li> </ul> </li> </ul>"},{"location":"research-design/mental_model/","title":"Mental Model","text":"<p>This section captures your current working theory of the biological or computational system under study. It's where you articulate how you think the system works even if that model is provisional or incomplete.</p>"},{"location":"research-design/mental_model/#current-conceptual-model","title":"Current Conceptual Model","text":"<ul> <li>How do you currently believe the relevant biological process or system operates?</li> <li>What entities (e.g., genes, pathways, cell types, clinical features) and relationships are central to the model?</li> <li>What is the directional flow of influence (e.g., variant \u2192 gene expression \u2192 phenotype)?</li> </ul>"},{"location":"research-design/mental_model/#visual-diagram-if-applicable","title":"Visual Diagram (if applicable)","text":"<ul> <li>Sketch or link to a diagram representing your model.</li> <li>Include key components (inputs, intermediates, outputs) and their hypothesized interactions.</li> <li>Label assumptions or areas of uncertainty.</li> </ul>"},{"location":"research-design/mental_model/#assumptions-holding-the-model-together","title":"Assumptions Holding the Model Together","text":"<ul> <li>Are relationships assumed to be linear, monotonic, or causal?</li> <li>Is stationarity, independence, or time-invariance assumed?</li> <li>Are proxies being used for latent or unmeasured variables?</li> <li>What known limitations or biological unknowns could disrupt this model?</li> </ul>"},{"location":"research-design/mental_model/#competing-or-simpler-models","title":"Competing or Simpler Models","text":"<ul> <li>Are there published models or frameworks that contrast with yours?</li> <li>Could a more parsimonious explanation (e.g., statistical artifact, batch effect) account for observed patterns?</li> <li>How would you test whether your model outperforms or is more explanatory than alternatives?</li> </ul>"},{"location":"research-design/overview/","title":"Project Overview","text":"<ul> <li>Project Title:</li> <li>Project Phase: (planning, prototyping, writing, etc.)</li> <li>Principal Investigator:</li> <li>Advisors / Collaborators:</li> <li>Goal of This Project:</li> </ul>"},{"location":"research-design/perspectives/","title":"Project Perspective","text":"<p>This section encourages you to reflect on the implicit and explicit viewpoints shaping the research. Scientific questions are often framed through a particular disciplinary, institutional, or societal lens. Being precise about perspective sharpens relevance and ethical clarity.</p>"},{"location":"research-design/perspectives/#primary-viewpoint","title":"Primary Viewpoint","text":"<ul> <li>Is the study primarily designed from the standpoint of a computational biologist, clinician, patient advocate, geneticist, or systems biologist?</li> <li>What questions are foregrounded due to this disciplinary lens?</li> <li>How might this affect data prioritization, interpretation, or tool development?</li> </ul>"},{"location":"research-design/perspectives/#stakeholders-and-impact","title":"Stakeholders and Impact","text":"<ul> <li>Who stands to benefit from this research (e.g., patients with rare disease, public health agencies, translational researchers)?</li> <li>Are there populations or use cases that may be marginalized or less well-served?</li> <li>Have user needs, equity, or accessibility concerns shaped design decisions?</li> </ul>"},{"location":"research-design/perspectives/#alternate-perspectives","title":"Alternate Perspectives","text":"<ul> <li>How would the experimental design, metrics of success, or outputs shift if the project were driven by a different audience (e.g., regulators, ethicists, industry)?</li> <li>What blind spots or assumptions emerge when viewed from another domain (e.g., social determinants of health, environmental exposures)?</li> <li>Are there interdisciplinary opportunities or tensions that need to be navigated?</li> </ul>"},{"location":"research-design/problem_statement/","title":"Problem Statement","text":"<p>Clearly articulating your problem sets the foundation for hypothesis generation, methodological decisions, and project relevance. This section should state the core research question in precise, technical terms.</p>"},{"location":"research-design/problem_statement/#core-question","title":"Core Question","text":"<ul> <li>What specific biological or computational question are you trying to answer?<ul> <li>Example: \u201cCan regulatory variant burden in immune-modulating genes explain unaffected carrier status in heritable PAH?\u201d</li> </ul> </li> </ul>"},{"location":"research-design/problem_statement/#scientific-context","title":"Scientific Context","text":"<ul> <li>What is known or debated about this problem?</li> <li>Why is this question unresolved or insufficiently answered by existing methods or data?</li> <li>Are there specific gaps in modeling, inference, interpretability, or integration?</li> </ul>"},{"location":"research-design/problem_statement/#timeliness-and-relevance","title":"Timeliness and Relevance","text":"<ul> <li>Why is this problem pressing now (e.g., new data availability, unmet clinical need, recent methodological advances)?</li> <li>What downstream implications would solving this problem have for science, health, or technology?</li> </ul>"},{"location":"research-design/problem_statement/#fit-and-scope","title":"Fit and Scope","text":"<ul> <li>What boundary conditions define this project (e.g., organism, disease model, data type)?</li> <li>How does the question align with broader themes in the field (e.g., rare variant interpretation, multimodal integration)?</li> <li>Are there specific populations, datasets, or mechanistic contexts that are particularly relevant?</li> </ul>"},{"location":"research-design/references/","title":"References","text":"<p>This file collects references specifically relevant to the research design of the project.</p>"},{"location":"research-design/references/#key-papers","title":"Key Papers","text":"<ol> <li>Author(s), Year. Title. Journal Name, Volume(Issue), Pages.</li> <li>Author(s), Year. Benchmark or methodological study related to this section.</li> </ol>"},{"location":"research-design/references/#usage-or-notes","title":"Usage or Notes","text":"<ol> <li>Brief notes on how or where this reference informs current work (e.g., tool parameter selection, statistical justification, biological interpretation).</li> </ol>"},{"location":"research-design/references/#to-review-or-vet","title":"To Review or Vet","text":"<ul> <li> Author(s), Year. Title. Still under consideration\u2014pending full read or discussion.</li> <li> Author(s), Year. Title. May be relevant if scope expands to [new topic].</li> </ul>"},{"location":"research-design/references/#versioning-notes","title":"Versioning Notes","text":"<ul> <li>Last updated: [YYYY-MM-DD]</li> <li>Curated by: [Name]</li> </ul>"},{"location":"research-design/system_structure/","title":"System Structure","text":"<p>Understanding the structure of the system under investigation provides a foundation for formulating hypotheses, selecting methods, and interpreting results. This section frames what type of system you\u2019re studying, what levels of organization it spans, and what units and dynamics are central to your analysis.</p>"},{"location":"research-design/system_structure/#type-of-system","title":"Type of System","text":"<ul> <li>What kind of system are you modeling or examining?<ul> <li>Biological (e.g., gene regulatory network, tumor microenvironment, neural circuitry)</li> <li>Regulatory (e.g., transcription factor activity, enhancer\u2013promoter interactions, signal transduction hierarchy)</li> <li>Computational (e.g., classification algorithm, simulation of gene-gene interaction effects, imputation model)</li> </ul> </li> </ul>"},{"location":"research-design/system_structure/#levels-of-analysis","title":"Levels of Analysis","text":"<ul> <li>What are the main organizational levels?<ul> <li>Example: variant \u2192 gene \u2192 pathway \u2192 phenotype</li> <li>Example: stimulus \u2192 cell state \u2192 tissue-level readout</li> <li>Example: sequence feature \u2192 model decision \u2192 performance metric</li> </ul> </li> <li>How are the levels connected or nested?<ul> <li>Example: Chromatin accessibility changes affect enhancer binding \u2192 shifts in gene expression \u2192 phenotype modulation</li> <li>Example: Sample-level omics \u2192 population-level trends</li> </ul> </li> </ul>"},{"location":"research-design/system_structure/#unit-of-analysis","title":"Unit of Analysis","text":"<ul> <li>What is the primary entity used for modeling or measurement?<ul> <li>Examples:<ul> <li>Genetic variant</li> <li>Single cell or cell line</li> <li>Timepoint or replicate</li> <li>Patient or cohort</li> <li>Algorithmic output (e.g., score, prediction, cluster)</li> </ul> </li> </ul> </li> <li>Will your project maintain a fixed unit across stages, or shift over time?<ul> <li>Example: From variants to genes to modules; From single cell to tissue-level summary</li> </ul> </li> </ul>"},{"location":"research-design/system_structure/#system-dynamics","title":"System Dynamics","text":"<ul> <li>Is the system static or changing across time, perturbation, or condition?<ul> <li>Static: A snapshot of gene expression across individuals</li> <li>Dynamic: Temporal expression under drug treatment, disease progression, or stimulation</li> </ul> </li> <li>How are transitions or state changes modeled or inferred?<ul> <li>Example: Time series of chromatin remodeling</li> <li>Example: Pseudotime ordering in single-cell transcriptomics</li> </ul> </li> <li>What assumptions are you making about system behavior?<ul> <li>Example: Assuming steady-state gene expression; assuming linear response to dosage</li> </ul> </li> </ul>"},{"location":"research-design/thesis_proposal_outline/","title":"Thesis Proposal Outline","text":"<p>This document provides a structured overview of your proposed research, modeled after NIH-style or institutional templates. Each section should be drafted with clarity, scientific rigor, and explicit rationale.</p>"},{"location":"research-design/thesis_proposal_outline/#1-background-and-significance","title":"1. Background and Significance","text":"<ul> <li>What biological or computational problem does your work address?</li> <li>Why is this an important and timely problem?</li> <li>How does your work build on, differ from, or fill gaps in existing literature?</li> </ul>"},{"location":"research-design/thesis_proposal_outline/#2-specific-aims","title":"2. Specific Aims","text":"<ul> <li>What are the 2\u20133 central aims that drive your project?<ul> <li>Aim 1: [e.g., Identify functional variants using integrated regulatory annotations]</li> <li>Aim 2: [e.g., Prioritize druggable pathways using expression and graph-based methods]</li> </ul> </li> </ul>"},{"location":"research-design/thesis_proposal_outline/#3-preliminary-data","title":"3. Preliminary Data","text":"<ul> <li>What early analyses, simulations, or observations support your proposal?</li> <li>Include any pilot studies, existing cohorts, or code prototypes.</li> </ul>"},{"location":"research-design/thesis_proposal_outline/#4-research-strategy","title":"4. Research Strategy","text":""},{"location":"research-design/thesis_proposal_outline/#approach","title":"Approach","text":"<ul> <li>What methods will you use to address each aim?</li> <li>What datasets, tools, and benchmarks will you rely on?</li> </ul>"},{"location":"research-design/thesis_proposal_outline/#pitfalls-and-alternatives","title":"Pitfalls and Alternatives","text":"<ul> <li>What are the known risks in your design or analysis pipeline?</li> <li>What contingency plans or backup methods will you use?</li> </ul>"},{"location":"research-design/thesis_proposal_outline/#5-references","title":"5. References","text":"<ul> <li>Include key primary literature, methods papers, and datasets you rely on.</li> <li>Format can follow journal or proposal-specific citation norms.</li> </ul>"},{"location":"research-design/unanswered_questions/","title":"Unanswered Questions","text":"<p>This section clarifies where uncertainty remains in your system or design. It helps delineate what parts of the project require deeper probing, model sensitivity checks, or exploratory analysis. Documenting these uncertainties early guides iteration and prevents premature conclusions.</p>"},{"location":"research-design/unanswered_questions/#open-or-speculative-aspects","title":"Open or Speculative Aspects","text":"<ul> <li>What key ideas or pathways remain poorly characterized?<ul> <li>Example: The mechanism linking methylation changes to phenotype remains indirect.</li> <li>Example: The causal role of observed co-expression is unclear\u2014correlation vs. regulation.</li> </ul> </li> </ul>"},{"location":"research-design/unanswered_questions/#assumptions-needing-validation","title":"Assumptions Needing Validation","text":"<ul> <li>What model or biological assumptions require stress-testing?<ul> <li>Example: Assuming batch-corrected RNA-seq preserves relative abundance.</li> <li>Example: Assuming TF-gene linkages from public databases apply to your cell type.</li> </ul> </li> </ul>"},{"location":"research-design/unanswered_questions/#black-box-elements","title":"Black Box Elements","text":"<ul> <li>What components of your approach or system are opaque or hard to interpret?<ul> <li>Example: Feature importance in a deep learning model.</li> <li>Example: Gene prioritization steps within a commercial tool.</li> <li>Example: Pre-trained embeddings from a language model applied to genomic sequence.</li> </ul> </li> </ul>"},{"location":"research-design/unanswered_questions/#plans-to-reduce-uncertainty","title":"Plans to Reduce Uncertainty","text":"<ul> <li>What follow-up experiments or analyses could clarify these questions?<ul> <li>Example: Run perturbation experiments to test regulator-target relationships.</li> <li>Example: Compare multiple algorithms to identify stable findings.</li> </ul> </li> </ul>"},{"location":"research-design/working_hypotheses/","title":"Working Hypotheses","text":"<p>This section frames your project\u2019s guiding testable ideas. Each hypothesis should be clearly stated and falsifiable, grounded in prior knowledge or theory. Consider how each might be tested, refined, or rejected as evidence accumulates.</p>"},{"location":"research-design/working_hypotheses/#primary-hypothesis","title":"Primary Hypothesis","text":"<ul> <li>What is your main mechanistic or predictive claim?<ul> <li>Example: \"Variants in chromatin remodeling genes reduce penetrance in known monogenic disorders.\"</li> <li>Example: \"Pathway-level differential activity in WNT signaling distinguishes disease subtypes.\"</li> </ul> </li> </ul>"},{"location":"research-design/working_hypotheses/#alternative-hypotheses","title":"Alternative Hypotheses","text":"<ul> <li>What competing or secondary explanations are plausible?<ul> <li>Example: \"Noncoding regulatory variation explains observed expression shifts.\"</li> <li>Example: \"Technical artifact or population structure, not true biological signal, drives association.\"</li> </ul> </li> </ul>"},{"location":"research-design/working_hypotheses/#falsifiability-criteria","title":"Falsifiability Criteria","text":"<ul> <li>What type of result would falsify each hypothesis?<ul> <li>Example: Lack of enrichment in expected gene sets under multiple models.</li> <li>Example: No signal in matched control datasets or independent validation cohort.</li> <li>Example: Failure to reproduce pathway signal across multiple quantification methods.</li> </ul> </li> </ul>"},{"location":"results/audience_pitches/","title":"Communication Pitches","text":"<ul> <li>2-sentence summary for expert in your field:</li> <li>1-sentence summary for general science audience:</li> <li>Lay explanation for stakeholders:</li> </ul>"},{"location":"results/deferred_features/","title":"Deferred Features or Extensions","text":"<ul> <li>Unbuilt but promising directions:</li> <li>Modular add-ons:</li> <li>Follow-up studies:</li> </ul>"},{"location":"results/interpretation_notes/","title":"Interpretation Notes","text":"<ul> <li>How findings relate to hypotheses:</li> <li>Alternate explanations:</li> <li>Future experiments needed:</li> </ul>"},{"location":"results/metaphors_and_visuals/","title":"Visual Analogies","text":"<ul> <li>Visual or metaphor for system or result:</li> <li>Diagram or figure references:</li> </ul>"},{"location":"results/summary_findings/","title":"Summary of Findings","text":"<p>Use this document to synthesize core results. Focus on clarity and interpretation rather than raw output.</p>"},{"location":"results/summary_findings/#key-results","title":"Key Results","text":"<ul> <li>What are the main findings so far?<ul> <li>e.g., \u201cVariants in mitochondrial genes are enriched in unaffected carriers.\u201d</li> <li>e.g., \u201cModule 3 (immune-related) is inversely associated with disease severity.\u201d</li> </ul> </li> </ul>"},{"location":"results/summary_findings/#statistical-and-biological-relevance","title":"Statistical and Biological Relevance","text":"<ul> <li>Which results are statistically significant, and how were they tested?</li> <li>What is their biological meaning or implication?</li> <li>Do findings align with prior literature, or do they suggest a new mechanism?</li> </ul>"},{"location":"results/summary_findings/#links-to-figures-or-tables","title":"Links to Figures or Tables","text":"<ul> <li>Where can key visuals or outputs be found?<ul> <li> Figure 1: Volcano plot of DEGs</li> <li> Table S2: List of enriched pathways</li> <li> Supplement: Code used to generate survival analysis</li> </ul> </li> </ul>"},{"location":"tracking/anticipated_qe_questions/","title":"Anticipated Questions","text":"<p>Use this document to prepare for high-stakes, committee-level questions. These prompts assume a sophisticated audience.</p> <p>Focus on rigor, defensibility, and awareness of limitations or alternatives.</p>"},{"location":"tracking/anticipated_qe_questions/#study-design","title":"Study Design","text":"<ul> <li>Can you defend how this design supports causal inference given your use of randomization, matching, or longitudinal tracking?</li> <li>What latent confounders, such as unmeasured covariates or differential loss to follow-up, might still bias your comparisons?</li> <li>If your intervention assignment were subject to clinical discretion or batch effects, how would that alter interpretation?</li> <li>Does your design account for informative censoring or data missing not at random (MNAR) in your patient- or sample-level metadata?</li> </ul>"},{"location":"tracking/anticipated_qe_questions/#hypothesis-and-scope","title":"Hypothesis and Scope","text":"<ul> <li>Is your central hypothesis grounded in a defined regulatory mechanism, pathway perturbation, or transcriptional program?</li> <li>Could your hypothesis be interpreted as post hoc pattern mining rather than pre-specified causal modeling?</li> <li>Can you pose a falsifiable alternative hypothesis consistent with current omics literature or known network topology?</li> <li>Are there biologically meaningful null models (e.g., randomized gene sets, permuted genotype-phenotype links) that you have not tested?</li> </ul>"},{"location":"tracking/anticipated_qe_questions/#sampling-and-generalizability","title":"Sampling and Generalizability","text":"<ul> <li>How might genetic ancestry, tissue source, or environmental exposure influence generalizability to external datasets?</li> <li>Could survival bias, inclusion based on diagnostic or treatment criteria, or data completeness thresholds affect effect estimates?</li> <li>What cross-validation schemes or out-of-sample predictions are you using to assess portability across biospecimens or cohorts?</li> </ul>"},{"location":"tracking/anticipated_qe_questions/#tool-and-pipeline-justification","title":"Tool and Pipeline Justification","text":"<ul> <li>What empirical benchmarks (e.g., DREAM challenges, gold-standard gene lists, synthetic spike-ins) validate the accuracy of your tool?</li> <li>Have you tested pipeline robustness under adversarial inputs, class imbalance, or corrupted labels?</li> <li>What distributional, sparsity, or independence assumptions are required by your algorithm, and are they satisfied in your omics matrix?</li> </ul>"},{"location":"tracking/anticipated_qe_questions/#model-assumptions-and-sensitivity","title":"Model Assumptions and Sensitivity","text":"<ul> <li>How are you assessing identifiability in the presence of multicollinearity, dropout, or latent variable structure?</li> <li>Have you run diagnostic checks (e.g., residual plots, permutation tests, bootstrapped estimates) to evaluate model calibration and variance?</li> <li>If model convergence fails or the optimization landscape is degenerate, how will you adapt your inference strategy?</li> </ul>"},{"location":"tracking/anticipated_qe_questions/#ethical-and-practical-considerations","title":"Ethical and Practical Considerations","text":"<ul> <li>How does your sampling strategy risk underrepresenting ancestrally diverse, low-resource, or clinically complex populations?</li> <li>Have you stratified performance metrics (e.g., AUC, F1, calibration error) by subgroup to assess algorithmic fairness?</li> <li>What ethical review is required if your findings suggest prognostic or actionable results in patient subgroups?</li> </ul>"},{"location":"tracking/anticipated_qe_questions/#edge-case-scenarios","title":"Edge Case Scenarios","text":"<ul> <li>How will you interpret a gene module or signature that achieves high predictive accuracy but has no known biological annotation?</li> <li>What if your key differential expression result replicates in only a subset of validation tissues or datasets?</li> <li>Can you resolve conflicting evidence when one modality (e.g., expression) supports your hypothesis but another (e.g., methylation or proteomics) does not?</li> <li>If your transcription factor inference identifies multiple regulators with overlapping binding sites, how will you prioritize them?</li> </ul>"},{"location":"tracking/anticipated_qe_questions/#broader-impact-and-rigor","title":"Broader Impact and Rigor","text":"<ul> <li>Which simplifying assumptions in variant interpretation, pathway enrichment, or transcription factor inference does your work relax or test?</li> <li>What theoretical advance (e.g., improved causal graph structure, multi-omic fusion, dimensionality reduction) does your method provide?</li> <li>How does your work contribute to reproducibility, scalability, or interpretability in computational biology pipelines?</li> <li>Can you articulate how your findings advance mechanistic understanding, clinical translation, or therapeutic discovery in your field?</li> </ul>"},{"location":"tracking/anticipated_qe_questions/#backup-and-contingency-plans","title":"Backup and Contingency Plans","text":"<ul> <li>If a required omics dataset is deprecated, missing metadata, or withdrawn from dbGaP/GEO, what secondary datasets can you use?</li> <li>Which preprocessing decisions (e.g., normalization, gene filtering, batch correction) are most sensitive in downstream outputs?</li> <li>How will you interpret your results if your primary hypothesis is only weakly supported but exploratory findings are strong?</li> <li>What alternative analyses (e.g., unsupervised clustering, pathway enrichment) can you pivot to if your primary model fails to converge?</li> <li>If your primary tool fails to run on a critical dataset, what are your fallback options for analysis?</li> </ul>"},{"location":"tracking/committee_feedback_log/","title":"Committee Feedback","text":"<p>Document key discussions with your thesis or dissertation committee. Each heading corresponds to a meeting, and subpoints capture major suggestions, concerns, or follow-up tasks. Use this to track alignment, revisions, and evolving expectations.</p>"},{"location":"tracking/committee_feedback_log/#meeting-on-date","title":"Meeting on [DATE]","text":"<p>Attendees: [Names of faculty present] Main Discussion:</p> <ul> <li>[What was discussed in depth?]  </li> <li>[Any strong opinions, recommendations, or cautions?]  </li> <li>[Concerns raised around feasibility, rigor, or scope?]</li> </ul> <p>Follow-up Questions:</p> <ul> <li>[What should be clarified or explored before the next meeting?]  </li> <li>[Did the committee suggest a new angle or method?]</li> </ul> <p>Action Items:</p> <ul> <li>[What do you need to revise, add, or draft?]  </li> <li>[Which documents will be updated and by when?]</li> </ul>"},{"location":"tracking/committee_feedback_log/#meeting-on-date_1","title":"Meeting on [DATE]","text":"<p>Attendees: Main Discussion: Follow-up Questions: Action Items:  </p>"},{"location":"tracking/key_decisions/","title":"Key Decisions and Rationales","text":"Date Decision Reason"},{"location":"tracking/next_steps/","title":"Next Actions Log","text":"<p>Use this log to track discrete project updates tied to actionable steps. Each entry should reflect a moment where you identified what to do next, including what assumptions to test or decisions to make.</p>"},{"location":"tracking/next_steps/#entry-date-yyyy-mm-dd","title":"Entry Date: [YYYY-MM-DD]","text":""},{"location":"tracking/next_steps/#immediate-tasks","title":"Immediate Tasks","text":"<ul> <li>[List the next few tractable steps]<ul> <li>e.g., Run differential expression on refined sample set</li> <li>e.g., Draft summary of tool comparisons</li> </ul> </li> </ul>"},{"location":"tracking/next_steps/#assumptions-to-probe","title":"Assumptions to Probe","text":"<ul> <li>[What assumption or unknown are you testing next?]<ul> <li>e.g., That phenotype clustering aligns with pathway-level variation</li> </ul> </li> </ul>"},{"location":"tracking/next_steps/#decision-points","title":"Decision Points","text":"<ul> <li>[What choices are on the horizon? What data do you need to decide?]<ul> <li>e.g., Determine whether to integrate proteomic data at this stage</li> </ul> </li> </ul>"},{"location":"tracking/next_steps/#dependencies","title":"Dependencies","text":"<ul> <li>[What\u2019s blocking progress or tied to another task/person?]<ul> <li>e.g., Waiting on ethics approval to access patient-level annotations</li> </ul> </li> </ul>"},{"location":"tracking/next_steps/#entry-date-yyyy-mm-dd_1","title":"Entry Date: [YYYY-MM-DD]","text":""},{"location":"tracking/next_steps/#immediate-tasks_1","title":"Immediate Tasks","text":"<ul> <li>\u2026</li> </ul>"},{"location":"tracking/next_steps/#assumptions-to-probe_1","title":"Assumptions to Probe","text":"<ul> <li>\u2026</li> </ul>"},{"location":"tracking/next_steps/#decision-points_1","title":"Decision Points","text":"<ul> <li>\u2026</li> </ul>"},{"location":"tracking/next_steps/#dependencies_1","title":"Dependencies","text":"<ul> <li>\u2026</li> </ul>"},{"location":"tracking/project_timeline/","title":"Project Timeline","text":""},{"location":"tracking/project_timeline/#high-level-milestones","title":"\ud83d\udccc High-Level Milestones","text":"Milestone Target Date Status Notes Project idea formalized YYYY-MM-DD \u2705 Complete Hypothesis development YYYY-MM-DD \ud83d\udfe1 In Progress Reviewing recent literature Committee feedback requested YYYY-MM-DD \ud83d\udd1c Upcoming QE draft ready for review YYYY-MM-DD \u2b1c Not Started Aim 2 needs modeling clarity QE oral defense YYYY-MM-DD \u2b1c Not Started Tentative date TBD Manuscript outline YYYY-MM-DD \u2b1c Not Started Code &amp; data freeze YYYY-MM-DD \u2b1c Not Started For publication handoff"},{"location":"tracking/project_timeline/#gantt-style-view-optional","title":"\ud83d\udcc5 Gantt-style View (optional)","text":"<p>Use this tool or manually draw timelines if needed.</p>"},{"location":"tracking/risks_and_mitigation/","title":"Risks and Mitigation","text":"<p>Use this section to think ahead about potential project failures\u2014technical, biological, or logistical\u2014and how you\u2019ll respond if they emerge.</p>"},{"location":"tracking/risks_and_mitigation/#known-risks","title":"Known Risks","text":"<ul> <li>What are the top 2\u20133 foreseeable risks?<ul> <li>Example: Public dataset may lack full phenotype metadata.</li> <li>Example: Method may not scale to full cohort due to runtime or memory issues.</li> </ul> </li> </ul>"},{"location":"tracking/risks_and_mitigation/#mitigation-strategies","title":"Mitigation Strategies","text":"<ul> <li>What are the specific backup strategies if each risk occurs?<ul> <li>Example: Switch to a subset of phenotypes; use synthetic phenotypes for benchmarking.</li> <li>Example: Profile code early and substitute lighter-weight methods.</li> </ul> </li> </ul>"},{"location":"tracking/risks_and_mitigation/#dependencies","title":"Dependencies","text":"<ul> <li>What tools, datasets, collaborators, or timelines is your project reliant on?<ul> <li>Example: Access to controlled dbGaP dataset</li> <li>Example: Pipeline component under active development by another lab</li> </ul> </li> </ul>"},{"location":"tracking/risks_and_mitigation/#risk-evaluation-frequency","title":"Risk Evaluation Frequency","text":"<ul> <li>How often will you re-assess risks and revise plans?<ul> <li>Example: Monthly during major phases; after each code sprint; before abstract deadlines.</li> </ul> </li> </ul>"}]}